Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

JAK inhibitors effectively treat severe alopecia areata with manageable side effects.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.

Baricitinib is an effective treatment for severe alopecia areata.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

JAK inhibitors are effective treatments for alopecia areata.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

CS12192 effectively treats alopecia areata with better safety than current options.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

CTP-543 is generally safe for treating alopecia areata.

Blocking interferon-gamma might help treat various autoimmune diseases.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Retinoids can help treat skin pigmentation disorders by affecting melanin production.

Tofacitinib treatment for hair loss may worsen acne.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Xinyang Tablet improves heart function in sepsis by reducing inflammation.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.